JPMorgan Chase & Co. restated their neutral rating on shares of AstraZeneca plc (LON:AZN) in a report released on Monday morning.

Other research analysts have also issued reports about the stock. Citigroup Inc. restated a buy rating on shares of AstraZeneca plc in a research note on Thursday, June 23rd. Deutsche Bank AG restated a buy rating and set a GBX 5,600 ($69.31) price objective on shares of AstraZeneca plc in a research note on Tuesday, June 14th. Societe Generale restated a buy rating and set a GBX 6,900 ($85.40) price objective on shares of AstraZeneca plc in a research note on Friday, June 24th. Berenberg Bank boosted their price objective on shares of AstraZeneca plc from GBX 4,950 ($61.26) to GBX 5,400 ($66.83) and gave the stock a buy rating in a research note on Tuesday, July 12th. Finally, Bryan, Garnier & Co reiterated a buy rating on shares of AstraZeneca plc in a research note on Thursday, July 28th. Five analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of Hold and a consensus target price of GBX 4,937.91 ($61.11).

Shares of AstraZeneca plc (LON:AZN) opened at 5037.00 on Monday. AstraZeneca plc has a 12-month low of GBX 3,680.00 and a 12-month high of GBX 5,505.00. The stock’s 50 day moving average is GBX 5,003.64 and its 200 day moving average is GBX 4,455.02. The firm’s market cap is GBX 63.72 billion.

The firm also recently disclosed a dividend, which was paid on Monday, September 12th. Stockholders of record on Thursday, August 11th were issued a GBX 68.70 ($0.85) dividend. The ex-dividend date of this dividend was Thursday, August 11th. This represents a dividend yield of 1.37%.

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.